Cargando…
An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall surv...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736652/ https://www.ncbi.nlm.nih.gov/pubmed/31564802 http://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03 |